GSK Consent Decree Includes $650 Mil. Bond, Third-Party Inspections
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline appears to have negotiated a more favorable consent decree agreement with FDA compared to previous pharmaceutical companies facing similar action